Production of pure indinavir free base nanoparticles by a supercritical anti-solvent (SAS) method

Drug Development and Industrial Pharmacy

Volumn 40, Issue 12, 2014, Pages 1607-1615

  Imperiale, Julieta C ^a   Bevilacqua, Gabriela ^b   De Rosa, Paulo Tarso Vieira ^b   Sosnik, Alejandro ^a,c  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Drug dissolution; Drug solubility; HIV; Indinavir free base; Pure drug nanoparticles; Supercritical anti solvent method

Indexed keywords

ACETONE; CARBON DIOXIDE; INDINAVIR; NANOPARTICLE; SOLVENT;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG MANUFACTURE; DRUG SOLUBILITY; LIGHT SCATTERING; PARTICLE SIZE; PHARMACOLOGICAL PROCEDURES; SCANNING ELECTRON MICROSCOPY; SUPERCRITICAL ANTI SOLVENT METHOD; SUPERCRITICAL FLUID; X RAY DIFFRACTION; CHEMISTRY; PROCEDURES; SUPERCRITICAL FLUID CHROMATOGRAPHY; SYNTHESIS;

CHROMATOGRAPHY, SUPERCRITICAL FLUID; INDINAVIR; NANOPARTICLES; SOLVENTS; X-RAY DIFFRACTION;

EID: 84922243406     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2013.838581     Document Type: Article

References (58)

1. UNAIDS report on the global AIDS epidemic, Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization. Available from: http://www.unaids.org/en/ media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120-UNAIDS-Global-Report-2012-en.pdf [last accessed 28 April 2013].
2. Panel of clinical practices for treatment of HIV infection. Pan Am J Public Health 2001;10:426-35.
3. Delaney M. History of HAART-The true story of how effective multi-drug therapy was developed for treatment of HIV disease. Retrovirology 2006;3:S6.
4. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science 2009;323:1304-7.
5. Romanelli F, Hoven AD. Use of virostatics as a means of targeting human immunodeficiency virus infection. Curr Pharm Des 2006;12: 1121-7.
6. Geeraert L, Kraus G, Pomerantz RJ. Hide-And-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med 2008;59: 487-501.
7. Flexner C. HIV-protease inhibitors. N Engl J Med 1998;338: 1281-92.
8. Wu C-Y, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005;22:11-23.
9. Ruela Correa JC, D'Arcy DM, dos Reis Serra CH, Nunes Salgado HR. Darunavir: a critical review of its properties, use and drug interactions. Pharmacology 2012;90:102-9.
10. Lin JH. Role of pharmacokinetics in the discovery and development of indinavir. Adv Drug Deliv Rev 1999;39:33-49.
11. Johnson BD, Howard A, Varsolona R, et al. Indinavir sulfate. In: Brittain HG, ed. Analytical profiles of drug, substances and excipients. Vol. 26. San Diego: Academic Press; 1999:319-57.
12. de Carvalho e Silva B, Moreira de Campos LM, Pianetti GA. Development and validation of an alternative titration method for the determination of sulfate ion in indinavir sulfate. Quim Nova 2005; 28:54-6.
13. Singh P, Premkumar L, Mehrotra R, et al. Evaluation of thermal stability of indinavir sulphate using diffuse reflectance infrared spectroscopy. J Pharmaceutical Biomed Anal 2008;47: 248-54.
14. Ferreira da Silva RM, Morais de Medeiros FP, Nascimento TG, et al. Thermal characterization of indinavir sulfate using TG, DSC and DSC-photovisual. J Thermal Anal Calorim 2009;95: 965-8.
15. Yeh KC, Deutsch PJ, Haddix H, et al. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother 1998;42:332-8.
16. Arribas JR, Doroana M, Turner D, et al. on behalf of the panel members. Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting. AIDS Res Ther 2013;10:Art. 3.
17. Boyd M. Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role? Expert Opin Pharmacother 2007;8:957-64.
18. Salahuddin S, Kok DJ, Buchholz NN. Influence of body temperature on indinavir crystallization under loop of Henle conditions. J Antimicrobial Chemother 2007;59:114-17.
19. Prezista, European Medicines Agency. Available from: http://www. ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/human/000707/WC500041754.pdf [last accessed 13 Aug 2013].
20. das Neves J, Amiji MM, Bahia MF, Sarmento B. Nanotechnologybased systems for the treatment and prevention of HIV/AIDS. Adv Drug Del Rev 2010;62:458-77.
21. Gupta U, Jain NK. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv Drug Del Rev 2010;62:478-90.
22. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004;3:785-96.
23. Müller RH, Gohla S, Keck CM. State of the art of nanocrystals-special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm 2011;78:1-9.
24. Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol 2008; 36:43-8.
25. Kesisoglou F, Panmai S, Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Del Rev 2007;59:631-44.
26. Williart JF, Descamps M. Solid state amorphization of pharmaceuticals. Mol Pharmaceutics 2008;5:905-20.
27. Naylor A, Lewis AL, Illum L. Supercritical fluid-mediated methods to encapsulate drugs: recent advances and new opportunities. Ther Deliv 2011;2:1551-65.
28. Pasquali I, Bettini R, Giordano F. Solid-state chemistry and particle engineering with supercritical fluids in pharmaceutics. Eur J Pharm Sci 2006;27:299-310.
29. Charbit G, Badens E, Boutin O. Methods of particle production. In: York P, Kompella UB, Shekunov BY, eds. Supercritical fluid technology for drug product development (drugs and the pharmaceutical sciences). Vol. 138. New York: Marcel Dekker, Inc. 2004:159-212.
30. Fages J, Lochard H, Letourneau JJ, et al. Particle generation for pharmaceutical applications using supercritical fluid technology. Powder Technol 2004;141:219-26.
31. Yeo SD, Kim MS, Lee JC. Recrystallization of sulfathiazole and chlorpropamide using the supercritical fluid antisolvent process. J Supercrit Fluid 2003;25:143-54.
32. Rehman M, Shekunov BY, York P, Colthorpe P. Solubility and precipitation of nicotinic acid in supercritical carbon dioxide. J Pharm Sci 2001;90:1570-82.
33. Toteva MM, Zanon R, Ostovic D. Kinetics and mechanism of the hydrolytic degradation of indinavir: intramolecular catalysis. J Pharm Sci 2008;97:3810-19.
34. Sacchetin PSC, Morales AR, Moraes AM, Rosa PTV. Formation of PLA particles incorporating 17a-methyltestosterone by supercritical fluid technology. J Supercrit Fluid 2013;77:52-62.
35. Liu H, Pierre-Pierre N, Huo Q. Dynamic light scattering for gold nanorod size characterization and study of nanorod-protein interactions. Gold Bull 2012;45:187-95.
36. Van der Zande BMI, Dhont JKG, Bohmer MR, Philipse AP. Colloidal dispersions of gold rods characterized by dynamic light scattering and electrophoresis. Langmuir 2000;16:459-64.
37. Lehner D, Lindner H, Glatter O. Determination of the translational and rotational diffusion coefficient of rodlike particles using depolarized dynamic light scattering. Langmuir 2000;16:1689-95.
38. Hochman JH, Chiba M, Nishime J, et al. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther 2000;292: 310-18.
39. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26.
40. Imperiale JC, Chiappetta DA, Sosnik A. Novel mucoadhesive nanodrug delivery system for the sustained delivery of protease inhibitors in the treatment of HIV. OBI 2011-2nd Workshop on biomaterials, artificial organs and tissue engineering; 2011 Sep 28-30, Mar del Plata, Argentina.
41. Andujar P, Lanone S, Brochard P, Boczowski J. Respiratory effects of manufactured nanoparticles. Rev Maladies Resp 2011;28:e66-75.
42. de Marco I, Reverchon E. Influence of pressure, temperature and concentration on the mechanisms of particle precipitation in supercritical antisolvent micronization. J Supercrit Fluid 2011;58: 295-302.
43. Yang L, Sun Z, Zu Y, et al. Physicochemical properties and oral bioavailability of ursolic acid nanoparticles using supercritical antisolvent (SAS) process. Food Chem 2012;132:319-25.
44. Dowy S, Braeuer A, Reinhold-Lopez K, Leipertz A. In situ optical monitoring of the solution concentration influence on supercritical particle precipitation. J Supercrit Fluid 2010;55:282-91.
45. Braeuer A, Dowy S, Torino E, et al. Analysis of the supercritical antisolvent mechanisms governing particles precipitation and morphology by in situ laser scattering techniques. Chem Eng J 2011;173:258-66.
46. Kalani M, Yunus R. Application of supercritical antisolvent method in drug encapsulation: a review. Int J Nanomed 2011;6:1429-42.
47. Sui X, Wei W, Yang L, et al. Preparation, characterization and in vivo assessment of the bioavailability of glycyrrhizic acid microparticles by supercritical anti-solvent process. Int J Pharm 2012;423:471-9.
48. Lin JH, Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997;49:403-49.
49. Phillips DJ, Pygall SR, Cooper VB, Mann JC. Overcoming sink limitations in dissolution testing: a review of traditional methods and the potential utility of biphasic systems. J Pharm Pharmacol 2012; 64:1549-59.
50. Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 1999;186:119-25.
51. Yu LX, Crison JR, Amidon GL. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int J Pharm 1996;140:111-18.
52. Sosnik A, Chiappetta DA, Carcaboso A. Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead. J Control Release 2009;138:2-15.
53. Chiappetta DA, Carcaboso AM, Bregni C, et al. Indinavir-loaded phsensitive microparticles for taste masking: towards extemporaneous paediatric HIV/AIDS liquid formulations with improved patient compliance. AAPS Pharm Sci Tech 2006;10:1-6.
54. Sosnik A. Nanotechnology contributions to the pharmacotherapy of pediatric HIV: a dual scientific and ethical challenge and a still pending agenda. Nanomedicine (Lond.) 2010;5:833-7.
55. Sosnik A, Amiji M. Nanotechnology solutions for infectious diseases in developing nations. Adv Drug Del Rev 2010;62:375-7.
56. Sosnik A, Seremeta KP, Imperiale JC, Chiappetta DA. Novel formulation and drug delivery strategies for the treatment of pediatric poverty related diseases (PRDs). Expert Op Drug Deliv 2012;9:303-23.
57. Imperiale JC, Sosnik A. Nanoparticle-in-microparticle delivery systems (NiMDS): production, routes of administration and clinical potential. J Biomater Tissue Eng 2013;3:22-38.
58. Imperiale JC. Microencapsulation processes of protease inhibitors for the optimization of the pharmacotherapy of the Human Immunodeficiency Virus (HIV) [PhD Thesis]. Faculty of Pharmacy and Biochemistry, University of Buenos Aires; 2013.